AVI BioPharma appoints interim president and CEO
This article was originally published in Scrip
AVI BioPharma (US), a developer of RNA-based drugs, has appointed its chief financial officer, David Boyle, to the additional roles of interim president and chief executive officer. The appointment follows the resignation of Leslie Hudson. Anthony Chase, chairman of ChaseSource, has also joined AVI's board and its nominating and corporate governance committee, while Michael Forrest has stepped down. The company's board is now made up of seven directors, all of whom are independent.
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.